Streetbeat News

Corporate Responsibility

SPNS

Sapiens International Corporation has released an updated version of its reinsurance and analytics solution, aimed at improving operational efficiency, regulatory reporting, and strategic decision-making through enhanced business insights. This update is designed to meet the evolving demands of the market.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:48 am

LODE

Comstock has successfully completed the commissioning stages of its demonstration-scale production facility located in Silver Springs, Nevada. This marks a significant milestone for the company as it advances towards full-scale production.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:47 am

MRNA

Moderna announced plans to present data from its respiratory portfolio, including vaccines and vaccine candidates, as well as research on cytomegalovirus, at the upcoming ESCMID Global Congress. This presentation could highlight Moderna's advancements in vaccine development and its potential impact on public health.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:37 am

DJT

The accounting firm BF Borgers, contracted by Trump Media & Technology Group (NASDAQ:DJT) for auditing, has been reported by the Financial Times for spelling inconsistencies in regulatory filings, using 14 different versions of founder Ben F Borgers' name. This raises concerns about the firm's standards amidst allegations of stock manipulation in Trump Media & Technology Group. The company's stock closed at $35.67, up 9.52%.

Portfolio Pulse from Benzinga Neuro

April 25, 2024 | 11:37 am

HOUS

Anywhere Real Estate projects a minimum of $100M in cost savings for FY24, indicating a significant financial optimization effort.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:35 am

OPTN

Optinose announced a corporate update, expecting to achieve positive income from operations by 2025. Preliminary Q1 2024 XHANCE net product revenue is $14.9 million, a 26% increase from Q1 2023. Peak XHANCE revenues are anticipated to exceed $300 million, targeting ENT and Allergy specialists.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:29 am

PPBT

Purple Biotech announced that its Phase 2 study of CM24 for pancreatic cancer has been selected for a late-breaking abstract poster presentation at the ASCO 2024 Annual Meeting. This recognition could indicate significant progress in the company's cancer treatment research.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:25 am

ONCY

Oncolytics Biotech announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This development could signal positive progress in their research and potential for future growth.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:24 am

BMY

Bristol Myers Squibb announced a strategic productivity initiative aimed at achieving approximately $1.5 billion in cost savings. The majority of these savings will be reinvested to fund innovation and drive growth.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:08 am

HZO

MarineMax reported that its Q2 performance was negatively affected by ongoing softness in the marine market. The company is taking steps to reduce expenses without compromising customer experience and service, aiming to align its cost structure with the current market conditions.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 10:54 am